|1.||Fookes, Maria C: 1 article (06/2015)|
|2.||Cohen, Dani: 1 article (06/2015)|
|3.||Behar, Adi: 1 article (06/2015)|
|4.||Thomson, Nicholas R: 1 article (06/2015)|
|5.||Goren, Sophy: 1 article (06/2015)|
|6.||Bourgeois, A Louis: 1 article (09/2009)|
|7.||Gaston, J S Hill: 1 article (09/2009)|
|8.||Venkatesan, Malabi M: 1 article (09/2009)|
|9.||Walker, Richard I: 1 article (09/2009)|
|10.||Ryan, Edward T: 1 article (09/2009)|
|1.||Bacillary Dysentery (Shigellosis)
11/01/1995 - "is a safe, repeatable, and valid method of selecting Shigella vaccines and other immunoprophylactic agents that are likely to confer protection against natural shigellosis."
02/01/1991 - "Serological markers should be incorporated in epidemiologic studies of shigellosis and in the design and evaluation of future trials of potential anti-Shigella vaccines."
07/01/1976 - "Nevertheless, a properly designed controlled field trial, taking into account transmissibility of vaccine, in an institutional setting similar to Sunland is necessary to substantiate the role of oral shigella vaccines in control of institutional shigellosis."
09/01/2006 - "The heterogeneous distribution of Shigella species and serotypes suggest that multivalent or cross-protective Shigella vaccines will be needed to prevent shigellosis in Asia."
07/01/1987 - "It was concluded that, in this population, effective shigella vaccines may provide an important means of preventing epidemics of shigellosis in military units operating outside of permanent bases."
08/01/1990 - "Prior infection provided 100% protection against febrile illness (p = 0.05) and diarrhea (p = 0.04), thereby validating the volunteer model for assessing Shigella vaccines."
12/01/1983 - " The review covers cholera (motility and chemotaxis, mucosal adhesion, flagellar sheath protein, hemagglutinins, outer membrane proteins, enterotoxin production, quality and duration of infection derived immunity, immune response in humans, LPS, flagellar sheath protein, cholera lectin, other cholera hemagglutinins, outer membrane protein, previous cholera vaccines, killer whole cell vaccines, toxoids, combination vaccines, attenuated versus cholerae vaccines): enterotoxigenic Escherichia coli (ETEC) (entertoxins, O:H serotypes and enterotoxin phenotypes, colonization factors, immune response in humans, vaccines against ETEC, and toxiods); EPEC (vaccines against EPEC); Shigella (smooth LPS O antigen, epithelial cell invasiveness, Shigella toxin, and Shigella vaccines); and typhoid fever (caccines against typhoid fever). "
03/01/1949 - "Studies in dysentery vaccination; response of children to booster injections of Shigella vaccines."
03/01/1991 - "Clinical studies of shigella vaccines are difficult because of the many causes of dysentery in a population with a high rate of intestinal disease."
01/01/1971 - "A field trial of oral streptomycin-dependent mutant Shigella vaccines in five hyperendemic areas of Yugoslavia in 1969 confirmed the findings of earlier studies by demonstrating the effectiveness of these vaccines against dysentery. "
|5.||Intestinal Diseases (Diseases, Intestinal)
|2.||Streptomycin (Streptomycin Sulfate)
|3.||Shiga Toxin (Shigella Toxin)
|5.||O Antigens (O Antigen)
|8.||Membrane Proteins (Integral Membrane Proteins)
|9.||Immunologic Factors (Immunomodulators)
|10.||Histocompatibility Antigens (Histocompatibility Antigen)